Smart Agro 2025: BetterSeeds, first real revenue, and whether the mark now needs external proof
BetterSeeds is no longer just an R&D story: in 2025 it posted roughly $1.4 million of revenue. But the carrying mark stayed flat in dollars, with no fresh outside round and no new market-based price discovery.
Why BetterSeeds Deserves Its Own Follow-up
The main article argued that paper value does not become realizable value on its own. This follow-up isolates BetterSeeds because that is where the biggest holding sits: at year-end 2025 it represented about 26.2% of Smart Agro's assets, and it was carried at NIS 6.463 million.
That matters beyond portfolio construction. On the latest trading date, April 3, 2026, using a unit price of 153.2 agorot and 4,189,138 units outstanding, Smart Agro's own market cap was about NIS 6.4 million. In other words, BetterSeeds alone is carried at almost the same size as the market value of the whole partnership. So the question of whether that mark has earned new proof is not a side issue. It is close to the center of the entire story.
And 2025 did produce something real. BetterSeeds moved from sounding mostly like an R&D, regulatory, and fundraising story to a business that has started to generate revenue at a scale that can no longer be dismissed. But the same evidence set also shows the limit of that progress: commercialization is now visible, fresh external pricing is not.
What Actually Changed: Revenue Is Now Real Enough to Matter
The key change in 2025 is that BetterSeeds no longer sits only on platforms, field work, and regulatory ambition. The company is explicitly described as being in an early commercial stage, with revenue from gene-editing services and technology licensing. Quantitatively, revenue rose from about $334 thousand in 2024 to about $1.4 million in 2025. That is more than a fourfold increase.
That revenue jump also fits a clear management pivot. During 2025 the company froze its planned Series B raise because market conditions were making capital harder to raise, especially for Israeli companies in the sector, and instead shifted its focus toward expanding revenue, strategic partnerships, and alternative funding paths. That matters because 2025 revenue is not just a nice headline. It is supposed to be the company's practical answer to a market that was less willing to finance pure promise.
But this is also where the quality question starts. The disclosure does not stop at saying commercialization has begun. It also explains how the activity was funded in practice: Innovation Authority grants, gene-editing service revenue from subsidiaries, and the sale of a license to Syngenta. So yes, this is progress. Still, it is not yet a broad, diversified external revenue base that can independently re-underwrite valuation. Part of the revenue comes from within the company's own ecosystem, and another part comes from one named licensing transaction.
That is the key distinction. 2025 proved that BetterSeeds can generate revenue. It did not yet prove that the wider market is ready to put a new price on the business because of that revenue.
What Did Not Change: The Dollar Mark Stayed Frozen
This is where the picture becomes unusually clear. In Regulation 8B of the annual filing, BetterSeeds is presented as a very material valuation item, and the same page shows that the subject value was $2.026 million just before the valuation date on June 30, 2025, and also $2.026 million on December 31, 2025. In shekels, the mark moved from NIS 6.832 million to NIS 6.463 million, but that was not a business re-rating. It was mainly FX translation.
Note 13 reinforces the same point. During 2025, the partnership recognized a NIS 926 thousand valuation expense on the BetterSeeds investment due to the change in the dollar-shekel exchange rate. There was no new up-round or down-round in dollar terms embedded in the year-end carry. Economically, that means 2025 progress was enough to avoid another cut, but not enough to produce a new mark.
That is a major difference. In a partnership like Smart Agro, moving from near-zero commercial evidence to roughly $1.4 million of revenue could, in theory, have come with a re-rating. In practice, it did not. The carrying value did not move up, did not reset downward in dollars, and did not receive a fresh outside anchor. It simply stayed where it was.
Why This Still Falls Short of External Proof
Precision matters here. There is no rule that valuation must immediately move once first revenue appears. Private markets often wait to see whether the first commercial year becomes a pattern. But in this case the absence of external proof is almost spelled out in the filings.
First, BetterSeeds received no new equity investment during 2025. Second, according to the loan disclosure, it also received no new loans during 2025 and up to the report date. So the year in which BetterSeeds finally showed meaningful commercial movement still did not include a financing event that forced outside investors to put a fresh price on the company.
Second, Regulation 8B itself gives investors very little beyond the end result. The valuation model is described only as a value based on an economic review, and the line for assumptions is left blank. That is not the same as saying the mark is wrong. It is a narrower point: the filing does not provide the market with a quantitative assumption set that would let investors judge how much of the carry rests on what has already happened, and how much rests on what management still hopes will happen next.
Third, the attached economic review explicitly says it is indicative, relies on data and representations provided to it, and does not offer the same level of certainty as audited financial statements. It also states that no independent verification of the completeness, timeliness, or reliability of that information was performed. That does not invalidate the work. It does mean the review supports the accounting carry rather than replacing the need for a genuine market event.
| What is already there | What is still missing |
|---|---|
| Early commercial activity and about $1.4 million of revenue in 2025 | A new outside funding round that creates market price discovery |
| A clear management pivot toward revenue after freezing the Series B | Full quantitative disclosure of the assumptions behind the mark in Regulation 8B |
| A Syngenta license sale and gene-editing services | A broader external recurring revenue base that reduces dependence on grants and internal ecosystem activity |
So the right description for 2025 is not "the value was proven." It is "the value held." That still matters. BetterSeeds is no longer just a science option. But it also has not yet reached the moment when outside capital says, in a fresh price, that the business deserves more.
What Needs to Happen Next for the Mark to Become Proof
The economic review adds one more important point: according to management, BetterSeeds plans to pursue a capital raise of about $10 million at a company valuation of $40 million by the end of 2026. That is the natural next proof point. If such a round actually closes, it would provide the first fresh external anchor in quite some time for what BetterSeeds is worth.
But a round is not the only path. Even without one, the valuation could earn more weight if 2026 shows that 2025 revenue was not a one-year starting point but the beginning of a broader pattern. For that to happen, the business needs more than continued grants, subsidiary service revenue, and one licensing transaction. It needs repeatable external revenue, and over time it needs licensing and royalty streams that match the business model the company is describing.
That is why the right label for the next year is straightforward: this is a proof year, not a mark-up year. BetterSeeds has already passed the test of whether it can generate any revenue at all. It still has not passed the test of whether there is a new outside price willing to validate the story.
Conclusion
BetterSeeds is not just another small holding inside the basket. It sits at the core of the current read because it is both Smart Agro's largest holding and a number that almost matches the partnership's own market cap. That is why the difference between first commercialization and actual proof changes the way the whole name is read.
The conclusion is simple: 2025 proved there is real commercial activity and first revenue at a scale that now matters. It still did not deliver fresh outside price discovery. As long as that remains true, the BetterSeeds carrying value may be a defensible accounting number, but it is not yet one with a fresh market stamp on it. The next round, or a broader run-rate of external revenue, is the next hurdle this story still has to clear.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.